| 2024 | 2023 | ||
| £’m | £’m | ||
Revenue | 3 | ||
Adjusted Group operating profit | |||
Net IAS 41 valuation movement on biological assets | 14 | ||
Amortisation of intangible assets | 10 | ( | ( |
Impairment of intangible assets | 10 | ( | ( |
Group operating profit | 4 | ||
Finance costs | 6 | ( | ( |
Share of net profit of joint venture | 13 | ||
Profit before tax | |||
Taxation | 7 | ( | ( |
Profit for the year | |||
| Earnings per share | |||
| On profit for the period: | |||
Basic | 9 | ||
Diluted | 9 |
| 2024 | 2023 | ||
| £’m | £’m | ||
Profit for the year | |||
| Other comprehensive (expense)/income | |||
| Other comprehensive (expense)/income to be reclassified to profit or loss in subsequent periods: | |||
| Cash flow hedges | |||
(Losses)/gains arising in the year | 19 | ( | |
Reclassification adjustments for (losses)/gains included in the income statement | 19 | ( | |
Income tax effect | 7 | ( | |
Net other comprehensive (expense)/income to be reclassified to profit or loss in subsequent periods | ( | ||
| Other comprehensive expense not to be reclassified to profit or loss in subsequent periods: | |||
Actuarial losses on defined benefit pension scheme | 25 | ( | |
Income tax effect | 7 | ||
Net other comprehensive expense not to be reclassified to profit or loss in subsequent periods | ( | ||
Other comprehensive expense | ( | ( | |
Total comprehensive income |
| 27 March | ||||
| 2023 | 2022 | |||
| 2024 | Restated* | Restated* | ||
| £’m | £’m | £’m | ||
| Non-current assets | ||||
Financial asset investment | 13 | |||
Investment in joint venture | 13 | |||
Intangible assets | 10 | |||
Defined benefit pension scheme surplus | 25 | |||
Property, plant and equipment | 11 | |||
Right-of-use assets | 12 | |||
Biological assets | 14 | |||
Total non-current assets | ||||
| Current assets | ||||
Biological assets | 14 | |||
Inventories | 15 | |||
Trade and other receivables | 16 | |||
Other financial assets | 17 | |||
Income tax receivable | ||||
Cash and short-term deposits | 26 | |||
Total current assets | ||||
Total assets | ||||
| Current liabilities | ||||
Trade and other payables | 18 | ( | ( | ( |
Other financial liabilities | 19 | ( | ( | ( |
Lease liabilities | 12 | ( | ( | ( |
Provisions | 20 | ( | ( | ( |
Income tax payable | ( | ( | ||
Total current liabilities | ( | ( | ( | |
| Non-current liabilities | ||||
Other payables | 18 | ( | ( | ( |
Other financial liabilities | 19 | ( | ( | ( |
Lease liabilities | 12 | ( | ( | ( |
Deferred tax liabilities | 7 | ( | ( | ( |
Provisions | 20 | ( | ( | ( |
Total non-current liabilities | ( | ( | ( | |
Total liabilities | ( | ( | ( | |
Net assets | ||||
| Equity | ||||
Called-up share capital | 22 | |||
Share premium account | ||||
Share-based payments | 24 | |||
Shares held in trust | 23 | ( | ||
Hedging reserve | ( | ( | ||
Retained earnings | ||||
Total equity attributable to owners of the Parent |
| 2024 | 2023 | ||
| £’m | £’m | ||
| Operating activities | |||
Profit for the year | |||
| Adjustments to reconcile Group profit for the year to net cash inflows from operating activities: | |||
Income tax expense | 7 | ||
Net finance costs | 6 | ||
Loss/(gain) on sale of property, plant and equipment | ( | ||
Loss on disposal of right-of-use asset | |||
Depreciation of property, plant and equipment | 11 | ||
Depreciation of right-of-use assets | 12 | ||
Amortisation of intangible assets | 10 | ||
Impairment of intangible assets | 10 | ||
Share-based payments | |||
Difference between pension contributions paid and amounts recognised in the income statement | ( | ||
Share of net profit of joint venture | ( | ||
Release of Government grants | ( | ( | |
Net IAS 41 valuation movement on biological assets | 14 | ( | ( |
Increase in biological assets | ( | ( | |
Decrease/(increase) in inventories | ( | ||
Increase in trade and other receivables | ( | ( | |
Increase in trade and other payables | |||
Cash generated from operations | |||
Tax paid | ( | ( | |
Net cash from operating activities | |||
| Cash flows from investing activities | |||
Acquisition of subsidiaries, net of cash acquired | 13 | ( | |
Payment of property, plant and equipment acquired on acquisition | 13 | ( | |
Purchase of financial asset investment | 13 | ( | |
Purchase of property, plant and equipment | ( | ( | |
Proceeds from sale of property, plant and equipment | |||
Net cash used in investing activities | ( | ( | |
| Cash flows from financing activities | |||
Interest paid | ( | ( | |
Proceeds from issue of share capital | |||
Own shares purchased | 23 | ( | |
Issue costs of long-term borrowings | ( | ||
(Repayment of)/proceeds from borrowings | ( | ||
Repayment of borrowings acquired | 13 | ( | |
Dividends paid | 8 | ( | ( |
Payment of lease capital | ( | ( | |
Payment of lease interest | ( | ( | |
Net cash used in financing activities | ( | ( | |
Net increase in cash and cash equivalents | 26 | ||
Cash and cash equivalents at beginning of year | 26 | ||
Cash and cash equivalents at end of year | 26 |
| Share | Share | Share-based | Shares held | Hedging | |||
| capital | premium | payments | intrust | reserve | Retained | Total | |
| Note | Note | Note | Note | Note | earnings | equity | |
| £’m | £’m | £’m | £’m | £’m | £’m | £’m | |
At 26 March 2022 as originally presented | ( | ||||||
Change in accounting policy | ( | ||||||
Total equity at the beginning of the financialyear (restated*) | ( | ||||||
Profit for the year | |||||||
Other comprehensive expense | ( | ( | |||||
Total comprehensive income | |||||||
Share-based payments | |||||||
| Exercise, lapse or forfeit of share-based | |||||||
payments (restated*) | ( | ||||||
Scrip dividend | |||||||
Share options exercised | |||||||
Dividends | ( | ( | |||||
Deferred tax related to changes in equity | ( | ( | |||||
Current tax related to changes in equity | |||||||
At 25 March 2023 (restated*) | |||||||
At 25 March 2023 as originally presented | |||||||
Change in accounting policy | ( | ||||||
| Total equity at the beginning of the financial | |||||||
year (restated*) | |||||||
Profit for the year | |||||||
Other comprehensive expense | ( | ( | |||||
Total comprehensive income | ( | ||||||
Share-based payments | |||||||
Shares acquired by Employee Benefit Trust | ( | ( | |||||
| Exercise, lapse or forfeit of share-based | |||||||
payments | ( | ||||||
Share options exercised | |||||||
Dividends | ( | ( | |||||
Deferred tax related to changes in equity | |||||||
Current tax related to changes in equity | |||||||
At 30 March 2024 | ( | ( |
| Significant estimates and assumptions: | |
| Share-based | Note 24 – measurement of share-based payments. |
| payments | The fair value of share-based payments is estimated using inputs including expected share price volatility, the expected life of the |
| options and the number of awards that will ultimately vest. This estimate is not expected to have a material impact on the next 12 months. | |
Pensions | Note 25 – pension scheme actuarial assumptions. |
| The valuation of the defined benefit pension scheme is determined using assumptions including mortality, discount rates and inflation. | |
Goodwill | Note 10 – intangible assets. |
| The carrying value of Goodwill is tested annually for impairment. For each cash-generating unit (‘CGU’) the recoverable amount | |
| is determined as the value-in-use. | |
| For value-in-use models, the sensitivity of the assumptions applied in the model, including the estimated risk-adjusted future pre-tax | |
| cash flows, which are derived from Board approved budgets, and the pre-tax discount rate applied, which represents the Group’s | |
| pre-tax weighted average cost of capital (WACC), carries most of the estimation uncertainty. | |
| Refer to Note 10 for the sensitivity analysis of key assumptions on the value-in-use calculations and impairment outcomes. | |
| Biological | Note 14 – growth rate assumptions used in the fair value model. |
| assets | Pigs |
| The key estimate in determining the fair value of pigs is market prices. | |
| Quoted (unadjusted) prices in an active market are no longer available for sucklers and weaners. The Group’s valuation model for | |
| sucklers and weaners is therefore a function of the UK Standard Pig Price (SPP) for finished pigs since historic data suggests that | |
| prices for sucklers, weaners and finished pigs were strongly correlated. The derived prices for sucklers and weaners are then adjusted | |
| to reflect the growth of the pigs through a straight-line interpolation based on age, to provide a value for the pigs at a particular stage | |
| of growth. As suckler and weaner prices are no longer observable in the market, management concludes these prices fall within Level | |
| 3 of the fair value hierarchy. Refer to Note 21 for key assumptions about unobservable inputs, their relationship to fair value and | |
| sensitivity analysis. | |
| The Group’s valuation model for finished pigs utilises quoted (unadjusted) prices in an active market. The prices are then adjusted | |
| to reflect the growth of the animals through straight-line interpolation between prices to provide a value for the finished pigs at a | |
| particular stage of growth. As the estimated weaner price used in the straight-line interpolation for finished pigs is no longer | |
| observable in the market, management concludes these prices fall within Level 3 of the fair value hierarchy. | |
| Poult ry | |
| Estimates in determining the fair value of poultry relate to market prices. | |
| The valuation for broiler birds uses recent transaction prices at various stages of development. The prices are then adjusted to reflect | |
| the growth of the birds through interpolation between the transaction prices. Interpolation is used as an approximate growth rate. | |
| Estimates relating to biological assets are not expected to have a material impact on the next 12 months. |
| Significant judgements: | |
| Share-based | Note 24 – measurement of share-based payments. |
| payments | The selection of valuation models requires the use of management’s judgement. The fair value of share-based payments is estimated |
| as at the date of grant using a Black-Scholes option pricing model or a stochastic option pricing model. | |
Goodwill | Note 10 - intangible assets |
| The level at which goodwill is tested for impairment involves judgement. Management assess the nature of the individual businesses | |
| as well as the internal information presented to the Board to determine the level at which goodwill is monitored for the purpose of | |
| goodwill impairment testing. Changes to this assessment could impact the value-in-use calculation, affecting the conclusion of | |
| whether assets’ carrying amounts are recoverable. Following a review completed earlier in the year, the goodwill impairment | |
| assessment for the Fresh Pork and Livestock CGUs is completed on a combined basis consistent to how it is monitored by the | |
| management. The resulting change does not impact management’s assessment of goodwill impairment considerations in the current | |
| period or prior years. | |
Pensions | Note 25 – pension scheme actuarial assumptions. |
| The Group has the right to recover any remaining surplus on the winding up of the pension scheme. The expected method of recovery | |
| of the recognised pensions surplus is through reduction in future contributions or recovery of any remaining surplus through a refund. | |
| Management have applied judgement on the scheme rules to conclude the Group has the right to a refund. The rules state that | |
| any surplus remaining in the hands of the Trustees may, at the discretion of the Trustees, be used to increase the pensions | |
| payable or contingently payable to Members and/or their Dependents. Any surplus remaining in the hands of the Trustees after | |
| making such provision (if any) shall be paid to the Employers. Management have formed the judgement, based on paragraph BC10 | |
| of IFRIC 14, that the right to the surplus is not affected by future acts that could change the amount of surplus that could ultimately | |
| be recovered. The Trustees ability to use discretion and choose to grant benefit improvements (thus reducing the surplus) has | |
| therefore not been anticipated and does not remove the Company’s unconditional right to the surplus. | |
| Alternative | Note 30 – alternative performance measures. |
| performance | Management apply judgement to identify the significant non-cash items to exclude when calculating adjusted performance measures. |
| measures | The Board believe alternative measures are useful as they exclude volatile, one-off and non-cash items. |
2024 | 2023 | |||||
£’m | Food | Other | Total | Food | Other | Total |
Revenue | 2,573.9 | 25.4 | 2,599.3 | 2,296.4 | 26.6 | 2,323.0 |
Adjusted operating profit/(loss) | 192.5 | ( 7. 4) | 185.1 | 146.3 | 0.2 | 146.5 |
Finance costs | (8.9) | – | (8.9) | (6.3) | (0.1) | (6.4) |
Share of net profit of joint venture | 0.4 | – | 0.4 | – | – | – |
Adjusted profit/(loss) before tax | 184.0 | (7. 4) | 176.6 | 140.0 | 0.1 | 140.1 |
Assets | 1,355.0 | 29.0 | 1,384.0 | 1,248.4 | 16.4 | 1,264.8 |
Liabilities | (446.2) | (26.3) | (472.5) | (410.6) | (11.3) | (421.9) |
Net assets | 908.8 | 2.7 | 911. 5 | 8 37.8 | 5.1 | 842.9 |
Depreciation | 79.0 | 2.7 | 81.7 | 67. 5 | 1.3 | 68.8 |
Property, plant and equipment and right-of-use asset additions | 120.0 | 6.0 | 126.0 | 105.4 | 3.5 | 108.9 |
| 2024 | 2023 | |
| £’m | £’m | |
UK | 2,543.7 | 2,236.2 |
Continental Europe | 24.9 | 36.7 |
Rest of world | 30.7 | 50.1 |
2,599.3 | 2,323.0 |
| 2024 | 2023 | |
| £’m | £’m | |
Cost of sales excluding net IAS 41 valuation movement on biological assets | 2,224.6 | 2,022.1 |
Net IAS 41 valuation movement on biological assets* | (2.2) | ( 7.6) |
Cost of sales | 2,222.4 | 2,014.5 |
Gross profit | 376.9 | 308.5 |
Selling and distribution costs | 100.0 | 94.8 |
Administrative expenses excluding amortisation and impairment of intangible assets | 95.3 | 69.5 |
Impairment of intangible assets | 15.4 | 3.0 |
Amortisation of intangible assets | 5.0 | 5.2 |
Administrative expenses | 115.7 | 77.7 |
Other operating income | (5.7) | (9.9) |
Total operating costs | 2,432.4 | 2 ,17 7.1 |
| 2024 | 2023 | |
| £’m | £’m | |
| Staff costs: | ||
Wages and salaries | 388.4 | 335.9 |
Social security costs | 35.8 | 30.9 |
Other pension costs | 9.7 | 8.6 |
433.9 | 375.4 |
| 2024 | 2023 | |
| Number | Number | |
Production | 9,720 | 9,194 |
Selling and distribution | 490 | 586 |
Administration | 828 | 642 |
11,038 | 10,422 |
| 2024 | 2023 | |
| £’m | £’m | |
Directors’ remuneration | 7.2 | 4.7 |
Aggregate gains made by Directors on exercise of share options | 2.8 | 1.7 |
Number of Directors receiving pension contributions under money purchase schemes | 1 | 2 |
| 2024 | 2023 | |
| £’m | £’m | |
| Finance costs: | ||
Bank interest paid and similar charges | 5.3 | 4.0 |
Total interest expense for financial liabilities not at fair value through profit or loss | 5.3 | 4.0 |
Net finance income on defined benefit pension surplus (Note 25) | – | (0.1) |
Lease interest | 3.6 | 2.5 |
Total finance costs | 8.9 | 6.4 |
| 2024 | 2023 | |
| £’m | £’m | |
| Current income tax: | ||
UK corporation tax on profit for the year | 37.8 | 20.2 |
Adjustments in respect of prior years | 0.7 | 5.6 |
Total current tax | 38.5 | 25.8 |
| Deferred tax: | ||
Origination and reversal of temporary differences | 7.5 | 5.1 |
Deferred tax rate change | – | 2.4 |
Adjustments in respect of prior years | (0.7) | (5.2) |
Total deferred tax | 6.8 | 2.3 |
Tax on profit | 45.3 | 28.1 |
| 2024 | 2023 | |
| £’m | £’m | |
| Recognised in Group statement of comprehensive income | ||
Deferred tax on revaluation of cash flow hedges | (0.1) | 0.1 |
Deferred tax on actuarial gains/(losses)on defined benefit pension scheme | 0.1 | (2.3) |
Corporation tax credit on actuarial losses on defined benefit pension scheme | (0.1) | (0.5) |
(0.1) | (2.7) | |
| Recognised in Group statement of changes in equity | ||
Deferred tax (credit)/charge on share-based payments | (1.4) | 0.9 |
Corporation tax credit on share options exercised | (0.5) | (0.8) |
(1.9) | 0.1 | |
Total tax credit recognised directly in equity | (2.0) | (2.6) |
| 2024 | 2023 | |
| £’m | £’m | |
Profit before tax | 158.4 | 139.5 |
Profit multiplied by standard rate of corporation tax in the UK of 25 per cent (2023: 19 per cent) | 39.6 | 26.5 |
| Effect of: | ||
Expenses which are not deductible for tax purposes | 1.9 | 0.8 |
Goodwill impairment | 3.8 | – |
Deferred tax rate change | – | 2.4 |
Non-taxable income | – | (0.3) |
Super deduction | – | (2.0) |
Adjustment in respect of prior years | – | 0.4 |
Share-based payments | – | 0.3 |
Total tax charge for the year | 45.3 | 28.1 |
| Restated | ||
| 2024 | 2023* | |
| £’m | £’m | |
| Deferred tax liability in the balance sheet | ||
Accelerated capital allowances | 29.2 | 19.5 |
Business combinations | 3.6 | 3.8 |
Losses | (0.6) | (0.5) |
Biological assets | (0.1) | (1.2) |
Right-of-use asset | 18.9 | 15.9 |
Right-of-use liability | (19.9) | (16.6) |
Other temporary differences | 0.2 | 0.4 |
Share-based payments | (5.2) | (2.7) |
Deferred tax on defined benefit pension scheme | (0.2) | (0.4) |
Customer relationships intangibles | 2.5 | 2.5 |
Deferred tax liability | 28.4 | 20.7 |
| 2024 | 2023 | |
| £’m | £’m | |
| Deferred tax liability in the balance sheet | ||
At 25 March 2023 | 20.7 | 19.7 |
Recognised in income statement | 7.5 | 7. 5 |
Prior year adjustment recognised in income statement | (0.7) | (5.2) |
Acquired on acquisitions in the year | 2.3 | – |
Recognised in statement of comprehensive income | – | (2.2) |
Recognised in statement of changes in equity | (1.4) | 0.9 |
At 30 March 2024 | 28.4 | 20.7 |
| 2024 | 2023 | |
| £’m | £’m | |
| Deferred tax in the income statement | ||
Accelerated capital allowances | 8.2 | 2.3 |
Business combinations | (0.1) | (0.1) |
Losses | 0.9 | (0.2) |
Biological assets | 0.6 | 1.9 |
Right-of-use asset | 2.9 | 2.0 |
Right-of-use liability | (3.3) | (2.2) |
Other temporary differences | 0.1 | – |
Share-based payments | (1.2) | 0.3 |
Deferred tax on defined benefit pension scheme | – | (0.1) |
Customer relationships intangibles | (1.3) | (1.6) |
Deferred tax charge | 6.8 | 2.3 |
| 2024 | 2023 | |
| £’m | £’m | |
| Declared and paid during the year: | ||
Final dividend for 2023 – 58.8p per share (2022: | 31.7 | 29.7 |
Interim dividend for 2024 – | 12.2 | 11.0 |
Dividends paid | 43.9 | 40.7 |
| Proposed for approval of Shareholders at the Annual General Meeting on 29 July 2024: | ||
Final dividend for 2024 – | 36.3 | 30.0 |
| 2024 | 2023 | |
| Thousands | Thousands | |
Basic weighted average number of shares | 53,776 | 53,461 |
Dilutive potential ordinary shares – share options | 187 | 129 |
53,963 | 53,590 |
| Customer | ||||
| Goodwill | Trademark | relationships | Total | |
| £’m | £’m | £’m | £’m | |
| Cost | ||||
At 27 March 2022 | 213.8 | 5.7 | 32.6 | 252.1 |
Fair value adjustments | (0.8) | – | 0.9 | 0.1 |
At 25 March 2023 | 213.0 | 5.7 | 33.5 | 252.2 |
Acquired on acquisitions | 5.7 | – | 5.0 | 10.7 |
At 30 March 2024 | 218.7 | 5.7 | 38.5 | 262.9 |
| Amortisation | ||||
At 27 March 2022 | – | 1.3 | 19.5 | 20.8 |
Amortisation | – | 1.1 | 4.1 | 5.2 |
Impairment | – | – | 3.0 | 3.0 |
At 25 March 2023 | – | 2.4 | 26.6 | 29.0 |
Amortisation | – | 1.0 | 4.0 | 5.0 |
Impairment** | 15.1 | – | 0.3 | 15.4 |
At 30 March 2024 | 15.1 | 3.4 | 30.9 | 49.4 |
| Net book value | ||||
At 26 March 2022 | 213.8 | 4.4 | 13.1 | 231.3 |
At 25 March 2023 | 213.0 | 3.3 | 6.9 | 223.2 |
At 30 March 2024 | 203.6 | 2.3 | 7.6 | 213.5 |
| 2024 | 2023 | |
| £’m | £’m | |
Fresh Pork | 21.8 | 21.8 |
Livestock* | 23.3 | 20.2 |
Cooked Meats | 90.2 | 90.2 |
Continental Fine Foods | 39.1 | 39.1 |
Premium Cooked Poultry | 9.2 | 9.2 |
Fresh Chicken | 13.7 | 13.7 |
Cranswick Pet Products** | – | 15.1 |
Other | 6.3 | 3.7 |
203.6 | 213.0 |
| Budgeted gross | Other operating | Pre-tax discount | |
| margin (£’m) | costs (£’m) | rate (%) | |
Fresh pork and livestock | (14%) | 15% | 20% |
Cooked meats | (4%) | 4% | 5% |
Continental Fine Foods | (5%) | 6% | 4% |
Premium Cooked Poultry | (12%) | 12% | 12% |
Fresh Chicken | (10%) | 10% | 11% |
Other | (11%) | 10% | 21% |
| Plant, | Assets in the | |||
| Freehold land | equipment and | course of | ||
| and buildings | vehicles | construction | Total | |
| £’m | £’m | £’m | £’m | |
| Cost | ||||
At 27 March 2022 | 239.1 | 418.5 | 57.9 | 715.5 |
Additions | 11. 3 | 34.1 | 38.1 | 83.5 |
Acquired on acquisition | – | 0.6 | – | 0.6 |
Transfers between categories | 22.0 | 47.0 | (69.0) | – |
Disposals | (0.1) | (13.4) | – | (13.5) |
At 25 March 2023 | 272.3 | 486.8 | 27.0 | 786.1 |
Additions | 6.6 | 35.8 | 49.0 | 91.4 |
Acquired on acquisitions | 22.7 | 8.0 | – | 30.7 |
Transfers between categories | 7.4 | 22.1 | (29.5) | – |
Disposals | (0.6) | (21.1) | – | (21.7) |
At 30 March 2024 | 308.4 | 531.6 | 46.5 | 886.5 |
| Depreciation | ||||
At 27 March 2022 | 43.7 | 237.0 | – | 280.7 |
Charge for the year | 6.8 | 47. 3 | – | 54.1 |
Relating to disposals | – | (12.8) | – | (12.8) |
At 25 March 2023 | 50.5 | 271.5 | – | 322.0 |
Charge for the year | 11.0 | 54.5 | – | 65.5 |
Relating to disposals | (0.6) | (19.3) | – | (19.9) |
At 30 March 2024 | 60.9 | 306.7 | – | 3 67. 6 |
| Net book amounts | ||||
At 26 March 2022 | 195.4 | 181.5 | 57.9 | 434.8 |
At 25 March 2023 | 221.8 | 215.3 | 27. 0 | 464.1 |
At 30 March 2024 | 247.5 | 224.9 | 46.5 | 518.9 |
| Plant, | |||
| Land and | equipment and | ||
| buildings | vehicles | Total | |
| £’m | £’m | £’m | |
| Cost | |||
At 27 March 2022 | 86.0 | 9.2 | 95.2 |
Additions | 23.1 | 2.3 | 25.4 |
Disposals | (1.6) | (2.7) | (4.3) |
At 25 March 2023 | 107.5 | 8.8 | 116.3 |
Acquired on acquisitions | 1.4 | – | 1.4 |
Additions | 26.9 | 7.7 | 34.6 |
Disposals | (11.8) | (2.8) | (14.6) |
At 30 March 2024 | 124.0 | 13.7 | 137.7 |
| Depreciation | |||
At 27 March 2022 | 25.1 | 4.6 | 29.7 |
Charge for the year | 12.2 | 2.5 | 14.7 |
Relating to disposals | (1.6) | (2.4) | (4.0) |
Onerous lease provision reversal | (0.4) | – | (0.4) |
Transfer between categories | (0.6) | 0.6 | – |
At 25 March 2023 | 34.7 | 5.3 | 40.0 |
Charge for the year | 13.3 | 2.9 | 16.2 |
Relating to disposals | (8.1) | (2.8) | (10.9) |
At 30 March 2024 | 39.9 | 5.4 | 45.3 |
| Net book amounts | |||
At 26 March 2022 | 60.9 | 4.6 | 65.5 |
At 25 March 2023 | 72.8 | 3.5 | 76.3 |
At 30 March 2024 | 84.1 | 8.3 | 92.4 |
| 2024 | 2023 | |
| £’m | £’m | |
| Lease liabilities: | ||
Current | 17.3 | 14.4 |
Non-current | 82.1 | 66.8 |
99.4 | 81.2 |
| 2024 | 2023 | |
| £’m | £’m | |
| Depreciation charge on right-of-use assets: | ||
Land and buildings | 13.3 | 12.2 |
Plant, equipment and vehicles | 2.9 | 2.5 |
16.2 | 14.7 | |
Interest expense (included in finance costs) | 3.6 | 2.5 |
| Provisional | |
| fair value | |
| £’m | |
| Net assets acquired: | |
Property, plant and equipment | 8.0 |
Right-of-use assets | 1.4 |
Customer relationships | 5.0 |
Trade and other receivables | 0.7 |
Bank and cash balances | 1.6 |
Bank loans | (1.7) |
Trade and other payables | (4.1) |
Lease liabilities | (1.4) |
Provisions | (0.6) |
Deferred tax liability | (1.7) |
| 7.2 | |
Goodwill arising on acquisition | 2.6 |
Total consideration | 9.8 |
| Satisfied by: | |
Initial cash consideration | 9.4 |
Deferred consideration | 0.4 |
| 9.8 | |
| Net cash outflow arising on acquisition: | |
Cash consideration paid | 9.4 |
Cash and cash equivalents acquired | (1.6) |
| 7.8 |
| Fair value | |
| £’m | |
| Net assets acquired: | |
Property, plant and equipment | 22.7 |
Investment in joint venture | 0.4 |
Biological assets | 7.5 |
Inventories | 1.0 |
Trade and other receivables | 2.3 |
Bank and cash balances | (3.1) |
Bank loans | (4.8) |
Trade and other payables | (16.9) |
Deferred tax liability | (0.6) |
| 8.5 | |
Goodwill arising on acquisition | 3.1 |
Total consideration | 11.6 |
| Satisfied by: | |
Initial cash consideration | 10.5 |
Deferred consideration | 1.1 |
| 11.6 | |
| Net cash outflow arising on acquisition: | |
Cash consideration paid | 11.6 |
Cash and cash equivalents acquired | 3.1 |
| 14.7 |
| Fair value | |
| £’m | |
| Net assets acquired: | |
Property, plant and equipment | 0.6 |
Inventories | 0.1 |
Trade and other payables | (0.1) |
Provisions | (0.1) |
| 0.5 | |
Goodwill arising on acquisition | – |
Total consideration | 0.5 |
| Satisfied by: | |
Initial cash consideration | 0.5 |
Deferred contingent consideration | – |
| 0.5 | |
| Net cash outflow arising on acquisition: | |
Cash consideration paid (included in cash flows from investing activities) | 0.5 |
Cash and cash equivalents acquired | – |
| 0.5 |
| Pigs | Chickens | Total | |
| £’m | £’m | £’m | |
At 26 March 2022 | 44.0 | 9.4 | 53.4 |
Increases due to purchases | 23.5 | 14.3 | 37.8 |
Decrease attributable to harvest | (238.2) | (181.1) | (419.3) |
Decrease attributable to sales | (1.7) | (1.9) | (3.6) |
Changes in fair value less estimated costs to sell | 241.0 | 169.8 | 410.8 |
At 25 March 2023 | 68.6 | 10.5 | 79.1 |
Increases due to purchases | 29.7 | 17.6 | 47. 3 |
Increases due to acquisition | 7.5 | – | 7.5 |
Decrease attributable to harvest | (298.5) | (196.8) | (495.3) |
Decrease attributable to sales | (6.8) | (1.5) | (8.3) |
Changes in fair value less estimated costs to sell | 278.6 | 181.2 | 459.8 |
At 30 March 2024 | 79.1 | 11.0 | 90.1 |
| 2024 | 2023 | ||
| £’m | £’m | ||
| Non-current biological assets: | |||
Pigs | 5.7 | 6.0 | |
Chickens | 0.7 | 0.3 | |
6.4 | 6.3 | ||
| Current biological assets: | |||
Pigs | 73.4 | 62.6 | |
Chickens | 10.3 | 10.2 | |
83.7 | 72.8 |
| 2024 | 2023 | |
| £’m | £’m | |
| Net IAS 41 valuation movement on biological assets* | ||
Changes in fair value of biological assets | 459.8 | 410.8 |
Biological assets transferred to cost of sales | (4 57.6) | (403.2) |
2.2 | 7.6 |
| 2024 | 2023 | |||
| Number | Number | |||
| Quantities at year end: | ||||
Breeding sows (Bearer biological assets) | 71,237 | 62,515 | ||
Boars | 1,315 | 1,132 | ||
Pigs (Consumable biological assets) | 755,051 | 655,212 | ||
Breeder chickens (Bearer biological assets) | 441,050 | 365,814 | ||
Broiler chickens (Consumable biological assets) | 6,007,274 | 5,332,477 | ||
Number of pigs produced in the year | 1,570,358 | 1,248,357 | ||
Number of chickens produced in the year | 61,985,710 | 59, | 367,8 | 4 8 |
| 2024 | 2023 | |
| £’m | £’m | |
Raw materials and work in progress | 70.7 | 73.5 |
Finished goods and goods for resale | 43.0 | 39.5 |
113.7 | 113.0 |
| 2024 | 2023 | |
| £’m | £’m | |
| Financial assets: | ||
Trade receivables | 295.0 | 265.5 |
Other receivables | 15.7 | 12.0 |
310.7 | 27 7. 5 | |
| Non-financial assets: | ||
Prepayments | 14.6 | 11.0 |
325.3 | 288.5 |
| Trade | Of which: | ||||
| receivables | Not due | Past due date in the following periods | |||
| Between | |||||
| Less than | 30 and 60 | More than | |||
| 30 days | days | 60 days | |||
£’m | £’m | £’m | £’m | £’m | |
2024 | 295.0 | 255.4 | 37.2 | 1.3 | 1.1 |
2023 | 265.5 | 221.2 | 35.7 | 3.6 | 5.0 |
| £’m | |
| Bad debt provision: | |
At 27 March 2022 | 2.8 |
Provided in year | 0.2 |
Released | (0.5) |
Utilised | – |
At 25 March 2023 | 2.5 |
Provided in year | 0.7 |
Released | (0.4) |
Utilised | (0.1) |
At 30 March 2024 | 2.7 |
| 2024 | 2023 | |
| £’m | £’m | |
| Current: | ||
Forward currency contracts | – | 0.1 |
– | 0.1 |
| 2024 | 2023 | |
| £’m | £’m | |
| Current: | ||
Trade payables | 180.0 | 167.6 |
Tax and social security | 11.1 | 5.4 |
Other creditors | 19.8 | 16.2 |
Commercial accruals* | 18.5 | 12.8 |
Other accruals | 80.2 | 66.3 |
Deferred income – Government grants | 0.4 | 0.2 |
310.0 | 268.5 | |
| Non-current: | ||
Deferred income – Government grants | 0.9 | 0.4 |
| Volume rebates | Advertising and | ||
| and similar | marketing | ||
| allowances | contributions | Total | |
| £’m | £’m | £’m | |
At 27 March 2022 | 8.5 | 2.4 | 10.9 |
Charged to income statement | 14.3 | 1.4 | 15.7 |
Paid | (12.4) | (1.4) | (13.8) |
At 25 March 2023 | 10.4 | 2.4 | 12.8 |
Charged to income statement | 22.3 | 6.9 | 29.2 |
Paid | (16.8) | (6.7) | (23.5) |
At 30 March 2024 | 15.9 | 2.6 | 18.5 |
| 2024 | 2023 | |
| £’m | £’m | |
| Current: | ||
Forward currency contracts | 0.2 | 0.1 |
Deferred and contingent consideration (Note 13) | 2.1 | – |
2.3 | 0.1 | |
| Non-current: | ||
Contingent consideration (Note 13) | – | 2.7 |
Amounts outstanding under revolving credit facility | 28.0 | 42.0 |
Unamortised issue costs | (0.9) | (1.5) |
27.1 | 43.2 |
| 2024 | 2023 | |
| £’m | £’m | |
| Movement on hedging instruments: | ||
(Losses)/gains arising in the year | (0.1) | 0.1 |
Reclassification adjustment for (losses)/gains included in the income statement | (0.1) | 0.3 |
(0.2) | 0.4 |
| 2024 | 2023 | |
| £’m | £’m | |
In one year or less | – | – |
Between one year and two years | – | – |
Between two years and five years | 28.0 | 42.0 |
28.0 | 42.0 | |
Unamortised issue costs | (0.9) | (1.5) |
27.1 | 40.5 |
| Lease | Other | Total | |
| provisions | provisions | provisions | |
| £’m | £’m | £’m | |
At 25 March 2023 | 2.7 | 0.8 | 3.5 |
On acquisition | 0.6 | – | 0.6 |
Created | 0.9 | – | 0.9 |
Utilised | (0.6) | – | (0.6) |
Released | – | – | – |
At 30 March 2024 | 3.6 | 0.8 | 4.4 |
| 2024 | 2023 | |
| £’m | £’m | |
Current liabilities | 1.8 | 0.8 |
Non-current liabilities | 2.6 | 2.7 |
4.4 | 3.5 |
| Level 1 | Level 2 | Level 3 | Total | |
| £’m | £’m | £’m | £’m | |
| At 30 March 2024 | ||||
Breeding sows (Bearer biological assets) | – | 12.2 | – | 12.2 |
Boars | – | 0.2 | – | 0.2 |
Finished pigs (Consumable biological assets) | – | – | 49.9 | 49.9 |
Sucklers and weaners (Consumable biological assets) | – | – | 16.9 | 16.9 |
Breeder chickens (Bearer biological assets) | – | 2.2 | – | 2.2 |
Broiler chickens (Consumable biological assets) | – | 8.2 | – | 8.2 |
Total biological assets | – | 22.8 | 66.8 | 89.6 |
| Level 1 | Level 2 | Level 3 | Total | |
| £’m | £’m | £’m | £’m | |
| At 25 March 2023 | ||||
Breeding sows (Bearer biological assets) | – | 13.0 | – | 13.0 |
Boars | – | 0.1 | – | 0.1 |
Finished pigs (Consumable biological assets) | – | 39.7 | – | 39.7 |
Sucklers and weaners (Consumable biological assets) | – | 15.7 | – | 15.7 |
Breeder chickens (Bearer biological assets) | – | 1.6 | – | 1.6 |
Broiler chickens (Consumable biological assets) | – | 8.2 | – | 8.2 |
Total biological assets | – | 78.3 | – | 78.3 |
| £’m | |
At 25 March 2023 | 55.4 |
Increase due to purchases | 21.4 |
Increase due to acquisition | 6.0 |
Decrease attributable to harvest | (292.1) |
Decreases attributable to sales | (6.8) |
Changes in fair value less estimated costs to sell | 282.9 |
At 30 March 2024 | 66.8 |
| 2024 | 2023 | |
| £’m | £’m | |
Net total gains or (losses) for the period recognised in profit or loss under ‘Change in fair value of biological assets’ | 6.4 | (0.9) |
Net change in unrealised gains or (losses) for the period recognised in profit or loss attributable to weaners, sucklers and finished pigs held at the end of the reporting period | 6.7 | (1.2) |
Fair value | Range of inputs | |||||
| 2024 | 2023 | Unobservable | 2024 | 2023 | Relationship of unobservable | |
Description | £’m | £’m | inputs | £’m | £’m | inputs to fair value |
Sucklers and weaners | 16.9 | 15.7 | Suckler price | 51.98 - 55.40 | 39.31 - 52.60 | The higher the market price, |
Weaner price | 56.70 - 64.69 | 56.61 - 61.93 | the higher the fair value | |||
Finished pigs | 49.9 | 39.7 | Finisher price | 182.83 - 215.19 | 139.85 - 198.54 |
| Fixed interest | ||||||
| Weighted | ||||||
| average | ||||||
| effective | At floating | |||||
| interest rate | Total | interest rates | 1 year or less | 1–2 years | 2–3 years | |
| % | £’m | £’m | £’m | £’m | £’m | |
| Financial liabilities: | ||||||
Revolving credit facility | 6.0% | (28.0) | (28.0) | – | – | – |
| Financial assets: | ||||||
Cash at bank | 0.0% | 27.0 | 27.0 | – | – | – |
(1.0) | (1.0) | – | – | – |
| Fixed interest | ||||||
| Weighted | ||||||
| average | ||||||
| effective | At floating | |||||
| interest rate | Total | interest rates | 1 year or less | 1–2 years | 2–3 years | |
| % | £’m | £’m | £’m | £’m | £’m | |
| Financial liabilities: | ||||||
Revolving credit facility | 3.3% | (42.0) | (42.0) | – | – | – |
| Financial assets: | ||||||
Cash at bank | 0.0% | 20.3 | 20.3 | – | – | – |
(21.7) | (21.7) | – | – | – |
2024 | 2023 | |||
| Book value | Fair value | Book value | Fair value | |
| £’m | £’m | £’m | £’m | |
Forward currency contracts liability (Note 17 and Note 19) | 0.2 | 0.2 | – | – |
Contingent consideration (Note 13 and Note 19) | 1.7 | 1.7 | 2.7 | 2.7 |
| Exchange | Fair value | |||
Currency | Amount | Maturities | rates | £’m |
Euros | €41.6m | 31 Mar 2024 – 01 Dec 2024 | 1.14 – 1.17 | (0.2) |
US Dollars | $3.0m | 16 April 2024 – 24 May 2024 | 1.26 – 1.27 | – |
| Increase/ | Effect on profit | |
| decrease | before tax | |
| in basis points | £’m | |
| 2024 | ||
Sterling | +10 0 | (0.8) |
-100 | 0.8 | |
| 2023 | ||
Sterling | +10 0 | (1.0) |
-100 | 1.0 |
| Less than | |||||
| 1 year | 1 to 2 years | 2 to 5 years | Over 5 years | Total | |
| £’m | £’m | £’m | £’m | £’m | |
Revolving credit facility | – | – | 28.0 | – | 28.0 |
Deferred and contingent consideration | 2.1 | – | – | – | 2.1 |
Trade and other payables | 310.0 | 0.6 | 0.3 | – | 310.9 |
Derivative financial instruments | 0.2 | – | – | – | 0.2 |
Lease liabilities | 19.5 | 18.0 | 42.5 | 34.7 | 114.7 |
331.8 | 18.6 | 70.8 | 34.7 | 455.9 |
| Less than | |||||
| 1 year | 1 to 2 years | 2 to 5 years | Over 5 years | Total | |
| £’m | £’m | £’m | £’m | £’m | |
Revolving credit facility | – | – | 42.0 | – | 42.0 |
Contingent consideration | – | 2.7 | – | – | 2.7 |
Trade and other payables | 268.5 | 0.2 | 0.2 | – | 268.9 |
Derivative financial instruments | 0.1 | – | – | – | 0.1 |
Lease liabilities | 15.6 | 14.1 | 32.4 | 27.4 | 89.5 |
284.2 | 17.0 | 74.6 | 27. 4 | 403.2 |
| 2024 | 2023 | 2024 | 2023 | |
| Number | Number | £’m | £’m | |
At beginning of year | 53,702,395 | 53,178,624 | 5.4 | 5.3 |
On exercise of share options | 302,549 | 382,925 | – | 0.1 |
Deferred Bonus Plan | 2,666 | – | – | – |
Scrip dividends | – | 140,846 | – | – |
At end of year | 54,007,610 | 53,702,395 | 5.4 | 5.4 |
Number | Exercise price | Exercise period | |
Savings related | 9,887 | 2,239p | March 2022 – October 2024 |
Savings related | 26,725 | 2,534p | March 2023 – October 2025 |
Savings related | 91,237 | 2,800p | March 2024 – October 2026 |
Savings related | 186,000 | 2,899p | March 2025 – October 2027 |
Savings related | 299,551 | 2,498p | March 2026 – October 2028 |
Savings related | 280,523 | 3,127p | March 2027 – October 2029 |
LTIP | 758,538 | Nil | June 2024 – July 2033 |
| 2024 | 2024 | 2023 | 2023 | |
| Number | WAEP (£) | Number | WAEP (£) | |
Outstanding as at beginning of year | 695,658 | – | 659,908 | – |
Granted during the year (i) | 286,295 | – | 268,622 | – |
Lapsed during the year | (84,867) | – | (2,453) | – |
Exercised during the year (ii) | (138,548) | – | (230,419) | – |
Outstanding as at end of year (iii) | 758,538 | – | 695,658 | – |
Exercisable at end of year | 11,749 | – | 24,382 | – |
| 2024 | 2024 | 2023 | 2023 | |
| Number | WAEP (£) | Number | WAEP (£) | |
Outstanding as at beginning of year | 898,138 | 26.58 | 880,349 | 27.04 |
Granted during the year (i) | 288,842 | 31.27 | 364,489 | 24.98 |
Lapsed during the year | (127,815) | 26.79 | (190,225) | 27. 8 9 |
Exercised during the year (ii) | (165,242) | 26.50 | (156,475) | 23.82 |
Outstanding as at end of year (iii) | 893,923 | 28.08 | 898,138 | 26.58 |
Exercisable at end of year | 75,991 | 27.27 | 61,817 | 25.33 |
2024 | LTIP | 2024 | SAYE | 2023 | LTIP | 2023 | SAYE | |
Dividend yield | 2.35% | 2.14% | 2.49% | 2.48% | ||||
Expected share price volatility | 22.65% | – 22.93% | 22.25% | – 25.35% | 22.70% | – 26.99% | 25.44% – 26.91% | |
Risk-free interest rate | 4.67% | – 5.05% | 3.32% | – 3.53% | 1.55% – | 1.63% | 3.50% – 3.63% | |
Expected life of option | 3 years | 3.42 – | 5.42 years | 3 years | 3.42 – 5.42 years | |||
Exercise prices | £nil | £31.27 | £nil | £24.98 |
| 2024 | 2023 | |
| £’m | £’m | |
Benefit obligation at the beginning of the year | 22.1 | 30.1 |
Interest cost | 1.0 | 0.9 |
| Remeasurement (gains)/losses: | ||
Actuarial gains arising from changes in financial assumptions | (1.8) | (9.4) |
Actuarial losses arising from changes in demographic assumptions | – | 0.2 |
Other experience items | 0.2 | 1.5 |
Benefits paid from plan | (0.7) | (1.2) |
Benefit obligation at the end of the year | 20.8 | 22.1 |
| 2024 | 2023 | |
| £’m | £’m | |
Fair value of plan assets at the beginning of the year | 22.3 | 38.4 |
Interest income | 1.0 | 1.0 |
Return on plan assets | (1.6) | (17.3 ) |
Recognition of loss at inception date of buy-in policy | – | (2.9) |
Employer contributions | – | 4.3 |
Benefits paid from plan | (0.7) | (1.2) |
Fair value of plan assets at the end of the year | 21.0 | 22.3 |
| 2024 | 2023 | |
| £’m | £’m | |
Present value of funded obligations | (20.8) | (22.1) |
Fair value of plan assets | 21.0 | 22.3 |
Net asset recorded in the balance sheet | 0.2 | 0.2 |
| 2024 | 2023 | |
| £’m | £’m | |
| Amounts recognised in the income statement: | ||
Interest cost | 1.0 | 0.9 |
Interest income | (1.0) | (1.0) |
Total pension income recognised in the income statement | – | (0.1) |
| Actual return on assets | ||
Actual return on plan assets | (0.6) | (16.3) |
| Amounts recognised in the Group statement of comprehensive income | ||
Actuarial (losses)/gains immediately recognised | – | (12.5) |
e) Principal actuarial assumptions 2024 | 2023 | |
Discount rate | 4.85% | 4.65% |
Rate of price inflation | 3.15% | 3.05% |
| Revaluation of deferred pensions: | ||
Benefits accrued prior to 1 January 1998 | 5.00% | 5.00% |
Benefits accrued after 1 January 1998 | 3.15% | 3.05% |
| Rate of compensation increase: | ||
Benefits accrued prior to 1 January 1997 | 3.00% | 3.00% |
Benefits accrued after 1 January 1997 | 3.15% | 3.05% |
Future expected lifetime of pensioner at age 65: | 2024 | 2023 |
| Current pensioners: | ||
Male | 20.9 | 20.9 |
Female | 23.8 | 23.8 |
| Future pensioners: | ||
Male | 22.2 | 22.2 |
Female | 25.2 | 25.2 |
| 2024 | 2023 | |
| £’m | £’m | |
Deferred pensioners | 12.3 | 13.2 |
Pensions in payment | 8.5 | 8.9 |
20.8 | 22.1 |
| 2024 | 2023 | |
| Fair value of | Fair value of | |
| plan assets | plan assets | |
| £’m | £’m | |
Annuities | 1.8 | 1.9 |
Cash | 0.5 | 0.5 |
Buy-in policy | 18.7 | 19.9 |
Total | 21.0 | 22.3 |
| At | Other | At | |||
| 26 March | Acquired on | non-cash | 30 March | ||
| 2023 | acquisition | Cash flow | changes | 2024 | |
| £’m | £’m | £’m | £’m | £’m | |
Cash and cash equivalents | 20.3 | (1.5) | 8.2 | – | 27.0 |
Bank loans | – | (6.5) | 6.5 | – | – |
Revolving credit facility | (40.5) | – | 14.0 | (0.6) | (27.1) |
Lease liabilities | (81.2) | – | 17.8 | (35.9) | (99.3) |
Net debt | (101.4) | (8.0) | 46.5 | (36.5) | (99.4) |
| At | Other | At | ||
| 27 March | non-cash | 25 March | ||
| 2022 | Cash flow | changes | 2023 | |
| £’m | £’m | £’m | £’m | |
Cash and cash equivalents | 0.2 | 20.1 | – | 20.3 |
Revolving credit facility | (36.4) | (3.6) | (0.5) | (40.5) |
Lease liabilities | (69.8) | 16.3 | ( 27.7 ) | (81.2) |
Net debt | (106.0) | 32.8 | (28.2) | (101.4) |
| 2024 | 2023 | |
| £’m | £’m | |
Not later than one year | 0.2 | 0.2 |
After one year but not more than five years | – | – |
After five years | – | – |
0.2 | 0.2 |
| 2024 | 2023 | |
| £’m | £’m | |
Short-term employee benefits | 8.2 | 5.9 |
Share-based payments | 3.6 | 1.3 |
11. 8 | 7.2 |
| 2024 | 2023 | ||
| £’m | £’m | Change | |
Revenue | 2,599.3 | 2,323.0 | +11.9 % |
Cranswick Mediterranean Foods Limited | (1.6) | – | |
Elsham Linc Limited | (4.7) | – | |
Froch Foods Limited | (1.2) | – | |
Like-for-like revenue | 2,591.7 | 2,323.0 | +11.6% |
| 2024 | 2023 | ||
| £’m | £’m | Change | |
Gross profit | 376.9 | 308.5 | +22.2% |
Net IAS 41 valuation movement | (2.2) | ( 7.6) | |
Adjusted gross profit | 374.7 | 300.9 | +24.5% |
| 2024 | 2023 | ||
| £’m | £’m | Change | |
Group operating profit | 166.9 | 145.9 | +14 . 4% |
Net IAS41 valuation movement | (2.2) | ( 7.6) | |
Amortisation of intangible assets | 5.0 | 5.2 | |
Impairment of intangible assets | 15.4 | 3.0 | |
Adjusted Group operating profit | 185.1 | 146.5 | +26.3% |
Depreciation of property, plant and equipment | 65.5 | 54.1 | |
Depreciation of right-of-use assets | 16.2 | 14.7 | |
Adjusted EBITDA | 266.8 | 215.3 | +23.9% |
| 2024 | 2023 | ||
| £’m | £’m | Change | |
Profit before tax | 158.4 | 139.5 | +13. 5% |
Net IAS41 valuation movement | (2.2) | ( 7.6) | |
Amortisation of intangible assets | 5.0 | 5.2 | |
Impairment of intangible assets | 15.4 | 3.0 | |
Adjusted profit before tax | 176.6 | 14 0.1 | +26.1% |
| 2024 | 2024 | 2023 | 2023 | |||
| 2024 | Basic | Diluted | 2023 | Basic | Diluted | |
| £’m | pence | pence | £’m | pence | pence | |
On profit for the year | 113.1 | 210.4 | 209.7 | 111.4 | 208.3 | 207. 8 |
Amortisation of intangible assets | 5.0 | 9.4 | 9.3 | 5.2 | 9.6 | 9.6 |
Tax on amortisation of intangible assets | (1.3) | (2.3) | (2.3) | (1.0) | (1.8) | (1.8) |
Net IAS 41 valuation movement | (2.2) | (4.2) | (4.1) | ( 7.6) | (14.2) | (14.2) |
Tax on net IAS 41 valuation movement | 0.6 | 1.0 | 1.0 | 1.9 | 3.6 | 3.6 |
Impairment of goodwill | 15.1 | 28.0 | 27.9 | – | – | – |
Impairment of acquired intangible assets | 0.3 | 0.6 | 0.6 | 3.0 | 5.6 | 5.6 |
Tax on impairment of acquired intangible assets | (0.1) | (0.1) | (0.1) | (0.6) | (1.1) | (1.1) |
On adjusted profit for the year | 130.5 | 242.8 | 242.0 | 112. 3 | 210.0 | 209.5 |
| 2024 | 2023 | ||
| £’m | £’m | Change | |
Net cash from operating activities | 228.4 | 153.0 | +49.3% |
Net interest paid | (5.0) | (3.8) | |
Free cash flow | 223.4 | 149.2 | +49.7% |
| 2024 | 2023 | ||
| £’m | £’m | Change | |
Free cash flow | 223.4 | 149.2 | +49.7% |
Non-growth capital expenditure | (22.1) | (36.4) | |
Net IAS 41 valuation movement | 2.2 | 7. 6 | |
Lease capital paid | (14.2) | (13.8) | |
Lease interest paid | (3.6) | (2.5) | |
185.7 | 104.1 | ||
Adjusted profit for the year | 130.5 | 112.3 | |
Free cash conversion | 142.3% | 92.7% | +4,960 bps |
| 2024 | 2023 | ||
| £’m | £’m | Change | |
Average opening and closing net assets | 877.2 | 805.6 | |
Average opening and closing net debt | 100.4 | 103.7 | |
Average opening and closing pension surplus | (0.2) | (4.2) | |
Average opening and closing deferred tax | 24.6 | 20.1 | |
1,002.0 | 925.2 | ||
Adjusted Group operating profit | 185.1 | 146.5 | |
Return on capital employed | 18.5% | 15.8% | +264 bps |